Company: IMCR
Filing Date: 2025-03-17
Form Type: 424B7
Source: 0001140361-25-008917
Chunk: 119

Company: Immunocore Holdings plc
Filing Date: 2025-03-17
Form: 424B7
Chunk 119
---
 Completion of      
 the Offering       |     |            |     | Ordinary        
 Shares          
 Beneficially    
 Owned           
 Prior to        
 the Offering    |     | Maximum      
 Number of    
 Ordinary     
 Shares       
 Registered   
 Hereunder    
 for Sale     |     |    Ordinary Shares 
 Beneficially Owned 
    Upon Completion 
    of the Offering |     |            |
|                                                     |     |                 |     |                 |     | Principal          
 Amount of          
 Notes              |     | Percentage |     |                 |     |              |     |             Number 
        Of Ordinary 
             Shares |     | Percentage |
| Entities affiliated with Baker Bros. Advisors LP(1) |     | $150,000,000(2) |     | $150,000,000(2) |     | —                  |     | —          |     | 2,511,460(3)    |     | 1,584,014(4) |     |          2,511,460 |     | 4.99%      |

| (1) | Baker Bros. Advisors LP (“the Adviser”) is the investment adviser to 667, L.P. (“667”) and Baker Brothers Life Sciences, L.P. (“Life Sciences”, and together with 667, the “Baker Funds”) and has the sole voting and investment power with respect to the securities held by the Baker Funds and thus may be deemed to beneficially own such securities. Baker Bros. Advisors (GP) LLC (the “Adviser GP”) is the sole general partner of the Adviser and thus may be deemed to beneficially own the securities held by the Baker Funds. The managing members of the Adviser GP are Julian C. Baker and Felix J. Baker, who may be deemed to beneficially own the securities held by the Baker Funds. The business address of the Adviser, the Adviser GP, Julian C. Baker and Felix J. Baker is 860 Washington Street, 3rd Floor, New York, NY 10014. |

| (2) | Includes $12,764,000 principal amount of notes held directly by 667 and $137,236,000 principal amount of notes directly held by Life Sciences. |

| (3) | Includes (i) 109,897 ordinary shares held in the form of ADS held directly by 667 and (ii) 1,405,421 ordinary shares held in the form of ADS held directly by Life Sciences. In addition, 667 directly